HDAC-IN-92

• Description :

  HDAC-IN-92 is a pan-HDAC inhibitor with an IC50 of 12.58 µM in A2780 cells. HDAC-IN-92 demonstrates broad-spectrum, notable cytotoxic activity against a range of human cancer cell lines, including ovarian, liver, and breast carcinomas. HDAC-IN-92 causes apoptosis and demonstrates a notable decrease in tumor cell colony formation. HDAC-IN-92 inhibits the formation of blood vessels in the chick chorioallantoic membrane (CAM) . HDAC-IN-92 exhibits anti-tumor effect in a 4T1 tumor-bearing mouse model. HDAC-IN-92 can be used for research targeting solid tumor[1].

• UNSPSC :

  12352005

• Target :

  Apoptosis; HDAC

• Related Pathways :

  Apoptosis; Cell Cycle/DNA Damage; Epigenetics

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Smiles :

  O=C(NO)C1=CC=C(/N=C/C2=CN=C(SCC3=CC=CC(F)=C3)N2C)C=C1

• Molecular Formula :

  C19H17FN4O2S

• Molecular Weight :

  384.43

• References & Citations :

  [1]Jamshidi Z, et al. Novel imidazolyl-hydroxamic acid Schiff base scaffold derivatives as histone deacetylase inhibitors: Design, synthesis, and biological assessment. Bioorg Chem. 2025 Sep;164:108879.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported